introduction
Malignant pleural mesothelioma (MPM) is an uncommon tumor characterized by locally aggressive behavior which leads to a fatal prognosis, but its incidence has increased in recent times within industrialized nations including Japan [1] [2] [3] [4] . The optimal management of resectable MPM continues to be an ongoing topic of debate with general agreement in regard to poor disease control by any single-modality therapy [5] . The current standard for possible cure of the disease has shifted to a multidisciplinary approach combining extrapleural pneumonectomy (EPP) with chemotherapy and/or radiotherapy. Because of the difficulty in administering adjuvant chemotherapy after EPP, we conducted trimodality therapy with neoadjuvant chemotherapy followed by EPP and hemithoracic radiotherapy [6] . Several studies have been reported on trimodality therapy, such as chemotherapy followed by EPP and radiotherapy for resectable T1-3 N0-2 M0 MPM, in which the median survival from the start of chemotherapy or from registration ranged from 14.0 to 25.5 months [7] [8] [9] [10] [11] . The MARS feasibility trial, which failed to meet the primary end-point of assigning 50 patients to EPP or non-EPP after induction chemotherapy within 1 year, suggested that EPP within the trimodality therapy offers no benefit and possibly harms the patients, with median survival from randomization of 14.4 months for the EPP group and 19.5 months for the non-EPP group [12] . Currently, the role of neoadjuvant chemotherapy followed by EPP for resectable MPM is controversial, and we need the selection criteria for those patients most likely to benefit from EPP after neoadjuvant chemotherapy. In unresectable MPM, early response evaluation by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) rather than by computed tomography (CT) is a promising method to predict the patient survival outcome [13] . To our knowledge, there are no data available using FDG-PET/CT in regard to metabolic response after neoadjuvant chemotherapy for resectable MPM. The purpose of this multicenter study was to evaluate the usefulness of metabolic response by FDG-PET/ CT after neoadjuvant chemotherapy in predicting prognosis for patients with resectable MPM who underwent EPP.
patients and methods
We enrolled 73 patients with clinical T1-3 N0-2 M0 malignant pleural mesothelioma who were scheduled for multimodality therapy comprising neoadjuvant platinum-based chemotherapy followed by EPP and postoperative hemithoracic radiotherapy. Patients were staged according to the system developed by the International Mesothelioma Interest Group [14] at two institutions (Hyogo College of Medicine and Hiroshima University) between 1 January 2004 and 31 December 2011. Among these patients, we excluded those who had not undergone EPP (n = 11) and those for whom the FDG-PET/CT data before or after neoadjuvant chemotherapy were lacking (n = 12). Ultimately, 50 patients were enrolled in this retrospective study (Figure 1 ). We obtained appropriate approval for this multicenter study from the Institutional Review Board of each institution, which waived the requirement for informed consent from individual patients for this retrospective review from a prospective database.
Patients were eligible for trimodality therapy if they had a histologically confirmed diagnosis of MPM, including all subtypes and clinical T1-3 N0-2 M0 disease considered to be completely resectable; no prior treatment with chemotherapy, surgery, or radiotherapy for the disease; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; a predicted postoperative forced expiratory volume in 1 s of >1000 ml; and adequate bone marrow, hepatic, renal, cardiac and respiratory function. Patients were staged with high-resolution CT (HRCT) scanning of the chest and abdomen, brain magnetic resonance imaging or CT, and FDG-PET/CT.
Neoadjuvant chemotherapy consisted of three or four cycles of cisplatinbased chemotherapy followed by HRCT and FDG-PET/CT restaging. Cisplatin (Nippon Kayaku Co., Ltd., Tokyo, Japan) plus pemetrexed was predominantly used for neoadjuvant chemotherapy. A surgery was carried out 3-6 weeks after the end of chemotherapy.
EPP was defined as an en bloc resection of the lung, pleura, pericardium, and diaphragm without entering the pleural cavity. Partial or no removal of the pericardium or diaphragm was sometimes carried out for a parietal pleural tumor separable from the pericardium or diaphragm. Previous biopsy sites were removed with limited chest wall resection.
Adjuvant hemithoracic radiotherapy was carried out within 12 weeks of surgery. Patients received three-dimensional conformal radiotherapy using a linear accelerator for 6-20 MV photon energies. A total dose of 54 Gy was delivered in 30 fractions of 1.8 Gy/day. The target volume included the hemithorax and chest wall incisions. 
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Postoperatively, all patients underwent a physical examination every 3 months, and CT of the chest and abdomen every 6 months.
HRCT
HRCT was carried out at baseline before neoadjuvant chemotherapy, and repeated after neoadjuvant chemotherapy. Chest images were obtained using 16-row multidetector CT independent of subsequent FDG-PET/CT examinations. High-resolution images of tumors were acquired using the following parameters: 120 kVp, 200 mA, section thickness 1-2 mm, pixel resolution 512 × 512, scanning time 0.5-1.0 s, and a high spatial reconstruction algorithm with a 20 cm field of view and mediastinal (level, 40 HU; width, 400 HU) window setting.
FDG-PET/CT
FDG-PET/CT imaging was carried out at baseline before neoadjuvant chemotherapy, and repeated after neoadjuvant chemotherapy. Patients fasted for at least 4 h before being intravenously injected with 3.7 MBq/kg of FDG, and they then rested for about 1 h before being scanned. Blood glucose was measured before tracer injection to ensure a level of <150 mg/ dl, and patients with blood glucose ≥150 mg/dl during FDG-PET/CT image acquisition were excluded. All the patients were assessed using an integrated FDG-PET/CT scanner, either Discovery ST16 (GE Healthcare) or GEMINI GXL (Philips Medical Systems). An unenhanced CT image of a 2-4 mm thick section that matched the PET images was obtained from the head to the pelvic floor of each patient using a standard protocol. Immediately after CT, PET covered the identical axial field of view (2-4 min per table position depending on the condition of the patient and scanner performance). Both PET and CT studies proceeded with normal tidal breathing. All PET images were reconstructed using an iterative algorithm with CT-derived attenuation correction using Fourier rebinning followed by ordered-subset expectation maximization. A maximum standardized uptake value (SUV max ) was established by drawing regions of interest (ROI) around the primary tumor on attenuation-corrected FDG-PET images and calculated using the dedicated software of the PET/CT scanner based on the following formula: SUV max = [C(μC i /ml)/ID(μC i )]/w, where C is defined as activity at a pixel within the tissue identified by ROI and ID is defined as the injected dose/kg body weight (w). We adopted SUV max in the present analysis because it is less variable than the mean SUV in terms of measurements [15] .
response evaluation
Radiologic response was assessed by HRCT after completion of neoadjuvant chemotherapy using unidimensional measurement of pleural thickness perpendicular to the chest wall or mediastinum and modified RECIST criteria [16] .
The metabolic response on FDG-PET/CT was measured after completion of neoadjuvant chemotherapy adjusted to modified RESICT criteria [16] . Complete resolution of FDG uptake within the tumor volume so that it was indistinguishable from the surrounding normal tissue was considered as a complete response (CR). A partial response (PR) was defined as a reduction of ≥30% in tumor FDG uptake. An increase in tumor SUV max of ≥20% within the ROI defined on the baseline scan, or the appearance of new FDG uptake in another region, was classified as progressive disease (PD). Stable disease (SD) was classified as an increase in tumor SUV max of <20% or a decrease of <30%.
statistical analysis
Data are presented as numbers (%) or mean ± standard deviation unless otherwise stated. Overall survival (OS) was calculated as the time (in days) from diagnostic biopsy until death from any cause; patients who were alive on the date of the most recent follow-up were censored on that date. The duration of OS was analyzed using the Kaplan-Meier method. The differences in OS were assessed using the log-rank test. To assess the potential independent effects of decreased SUV max on OS, we carried out multivariate analyses using the Cox proportional hazards model using variables with a P value of <0.1 in the univariate analyses; P < 0.05 was considered statistically significant. Data were statistically analyzed using SPSS software (version 10.5, SPSS Inc., Chicago, IL).
results
The characteristics of the 50 study patients are summarized in Table 1 . The mean follow-up period after diagnosis was 18.6 ± 13.5 months. The chemotherapy regimen was cisplatin plus pemetrexed in 47 (94%) patients and cisplatin, CPT-11, and doxorubicin (adriamycin) (Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan) in 3 (6%) patients. Patients received three to four cycles of neoadjuvant chemotherapy (3.3 ± 1.1 cycles).
According to modified RECIST criteria, 20 (40%) patients had an objective response [1 CR and 19 PR] , 28 (56%) were classified as SD and 2 (4%) had PD ( Table 2) .
FDG-PET/CT measurement identified 14 (28%) responders (1 CR and 13 PR), 20 (40%) patients with SD, and 16 (32%) patients with PD. All 50 patients underwent EPP. A complete macroscopic resection of the tumor (R0 or R1 resection) was achieved in 48 (96%) patients. Two (4%) patients had gross residual disease (R2 resection) remaining on the chest wall. One patient died after surgery (aortic hemorrhage), with a postoperative 30-day mortality rate of 2.0%. Major complications occurred in 16 (32%) patients including diaphragmatic hernia (n = 4), bronchopleural fistula (n = 3), intrathoracic hemorrhage (n = 2), empyema (n = 2), respiratory failure (n = 2), chylothorax (n = 1), cardiac hernia (n = 1), and heart failure (n = 1).
A total of 29 (58%) patients completed adjuvant hemithoracic radiation after EPP.
The median OS for all 50 patients was 20.5 months [95% confidence interval (CI), 15.0-26.0 months], with a 3-year OS rate of 34.2% from diagnosis ( Figure 2) .
No correlation was observed between OS and radiologic response with median OS for radiologic responders of 25.7 months (n = 20; 95% CI, 14.5-37.0 months; 3-year OS rate, Figure 3A ). In contrast, metabolic responders significantly correlated to OS with median OS for metabolic responders not reached (n = 14; 3-year OS rate, 60.0%) versus 18.7 months (n = 36; 95% CI, 13.3-24.2 months; 3-year OS rate, 26.5%) for non-responders (P = 0.025, Figure 3B ). The OS of patients with epithelioid subtype (n = 38; median OS, 22.4 months; 95% CI, 13.7-31.1 months; 3-year OS rate, 39.4%) was better than for those with non-epithelioid subtype (n = 12; median OS, 14.9 months; 95% CI, 9.4-20.4 months; 3-year OS rate, 0%, P = 0.072).
Univariate analysis of the OS in all patients included the variables such as age, sex, location (side), histology, clinical stage, tumor shrinkage by HRCT, and SUV max decrease by FDG-PET/CT (Table 3) . Epithelioid histology, tumor shrinkage, and SUV max decrease were potentially associated with a long OS (P < 0.1). Multivariate analysis that included histology and tumor shrinkage (model 1), or histology and SUV decrease (model 2) showed that epithelioid histology [hazard ratio (HR) 0.36; 95% CI, 0.14-0.97; P = 0.04] and SUV max decrease (HR 0.80; 95% CI, 0.67-0.95; P = 0.01) were independent prognostic factors for OS (Table 3) .
discussion
The median OS from diagnosis for all cohort patients in this study was 20.5 months, which is similar to the reported range of 18.0-27.5 months for subsets of patients undergoing EPP after neoadjuvant chemotherapy [7] [8] [9] [10] [11] [12] . In the MARS trial, the median OS of the non-EPP arm from the start of treatment was about 23.1 months [12] . The median OS of EPP patients for unselected resectable MPM is not always better than that of non-EPP patients. In a systematic review of EPP outcomes, the 30-day mortality rates ranged from 0% to 11.8%, and the perioperative morbidity rates ranged from 22% to 82% [17] . Although the 30-day mortality and morbidity rates were both relatively low (2% and 32%, respectively) in the current study, the median OS was not satisfactory. To avoid futile surgery with high mortality and morbidity, we need the criteria for selection of patients with potentially resectable MPM who may benefit from EPP.
The current study demonstrated that decreased SUV max as evaluated by FDG-PET/CT after neoadjuvant chemotherapy is an independent prognostic factor for patients with resectable MPM who underwent EPP. In patients with MPM who underwent EPP, decrease in SUV max was more useful in predicting prognosis than tumor shrinkage on HRCT by modified RECIST. Radiographically, MPM is difficult to evaluate, given the nonradical and inconsistent pattern of growth and response to treatment. Although the RECIST criteria have been developed and have become widely accepted and used in clinical trials, the application of these criteria in MPM could be variably interpreted by different investigators, and this may lead to unsatisfactory results [18] . Modified RECIST has now been developed to avoid difficult and ambiguous situations concerning the interpretation in clinical trials, and this successfully distinguished between the responders and the non-responders in regard to survival parameters [16] . However, measuring the tumor thickness of resectable MPM is sometimes more difficult than that of unresectable bulky MPM because the thickness of resectable MPM tumors is often subcentimeter. We failed to distinguish between the responders and the non-responders in regard to OS using the modified RECIST in this study. In unresectable MPM, it was reported that a significant correlation between the metabolic response as evaluated by PET assessment after two cycles of pemetrexed-based chemotherapy and the patient outcome as measured by time to progression (TTP) was observed, whereas the radiologic response assessed by CT scanning was not predictive of improved TTP [13] . The findings of our study in regard to resectable MPM are consistent with those of the above study on unresectable MPM [13] . This is the first paper to describe the significance of metabolic response for resectable MPM using FDG-PET/CT.
The cut-off value of SUV max decrease in defining the metabolic response is important in clinical practice. Although a 20%-25% decrease in tumor FDG uptake is a widely accepted definition in patients undergoing palliative chemotherapy, higher threshold values seem more appropriate for neoadjuvant therapy [19] . Therefore, at the cut-off value of 30% for metabolic response used in this study, there was a significant difference in OS between the metabolic responders and the non-responders. Regardless of the cut-off value, SUV max decrease as a continuous variable was an independent prognostic factor for OS, which indicates the importance of metabolic response in predicting the survival in patients with resectable MPM who underwent EPP. Considering the satisfactory 3-year OS rate of 60% for metabolic responders, a cut-off value of 30% seems to be suitable to define metabolic responders who may benefit from EPP.
There were some discrepancies between the radiologic response and the metabolic response. Nine (18%) radiologic responders were defined as metabolic non-responders, whereas three (6%) radiologic non-responders were defined as [20] [21] [22] . In our analysis, it was an independent factor for OS, and patients with this subtype had a better prognosis than those with the non-epithelioid subtype.
The limitations of our study include the relatively small number of patients, the retrospective nature of the study, and no comparison with pleurectomy/decortication (P/D) or nonsurgical patients. One of the controversies surrounding the treatment of resectable MPM is whether EPP is more effective than less extensive operations such as P/D [20, 23] . The survival of metabolic responders who underwent P/D or who did not undergo surgery is unknown in our study. Randomization to surgery versus no surgery after induction chemotherapy is very difficult in patients with resectable MPM [12] .
One of the limitations of this multicenter study in regard to the use of PET is the wide variation in SUV among institutions. Many factors such as preparation procedures, scan acquisition, image reconstruction, and data analysis can affect the SUV. Using the metabolic response, which is the ratio of change in SUV max , one can minimize the effect of SUV max discrepancies among institutions.
In conclusion, the epithelioid subtype and metabolic response after neoadjuvant chemotherapy are both independent prognostic factors for patients with resectable MPM who underwent EPP. Patients with a metabolic response or epithelioid subtype may be suitable candidates for EPP after neoadjuvant chemotherapy. Further confirmation in a large cohort is required.
